Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Berkson Medical LLC

Neither a doctor nor a teaching hospital

Research payments

$931,176

111 payments

Through program year 2025, Berkson Medical LLC is reported as receiving $931,176 in research payments, across 111 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $530,927 34
2024 Research $42,308 4
2023 Research $19,236 10
2022 Research $34,391 11
2021 Research $45,752 10
2020 Research $105,625 21
2019 Research $152,937 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $466,454 33 payments
  2. LEO Pharma AS $146,008 15 payments
  3. Eli Lilly and Company $126,512 7 payments
  4. AbbVie, Inc. $81,855 22 payments
  5. Stryker Corporation $59,393 23 payments
  6. GlaxoSmithKline, LLC. $31,030 8 payments
  7. Aerin Medical Inc. $19,925 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps $248,826 13 payments
  2. A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) $144,966 12 payments
  3. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ Ly3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on A Background Therapy With Intranasal Corticosteroids $77,073 2 payments
  4. Tralokinumab Vaccine Response Time $76,844 7 payments
  5. Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) $71,243 21 payments
  6. Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $66,429 7 payments
  7. Clarifix Registry $59,393 23 payments
  8. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Itepekimab in Adult Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps $42,263 6 payments
  9. A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis $32,115 1 payment
  10. A Randomised Phiii Study to Assess the Effect of 100 MG SC Mepolizumab $25,566 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record